Table 5 Summaries of clinical histories of patients with basal‐like tumours not responding to chemotherapy.

Case number	Disease‐free survival (months)	Site of relapse	Treatment after relapse of disease	Time relapse to death (months)	Overall survival (months)
1	8	LN	MVP (2 cycles) PD lung, breast, LN	5	13
			Ifosfamide (2 cycles) PD
			Paclitaxel (1 cycle) PD
			5‐FU (1 cycle) PD
			Docetaxel (1 cycle) PD
2	27	Liver, bone, LN	Vinorelbine (2 cycles)	2	29
3	60	Bone	Docetaxel (6 cycles) PD liver, lung, bone megestrol	7	67
4	37	Brain, lung	DXT brain docetaxel (4 cycles)	8	45
5	48	Bone	DXT bone	15	63
			Letrozole 2 months PD
			Paclitaxel (6 cycles) PD
			Exemestane 13 months PD brain
			DXT brain
			Capecitabine
6	19	Bilateral breast, axilla	Docetaxel (4 cycles)	7	26
			MVP (1 cycle)
7	5	Lung	Docetaxel (2 cycles)	5	10
8	16	Skin, axilla	FTI PD pericardial effusion	11	27
			Vinorelbine (2 cycles) PD chest wall
			Docetaxel (4 cycles) PD lung
			MVP (1 cycle)
9	28	Liver, lung	Vinorelbine/epirubicin (1 cycle)	0.8	28.8
10	7	Ipsilateral LN	Surgery	37	44
			Adjuvant FEC (6 cycles)
			PD skin
			Miftefosine 7 months PD
			Herceptin 10 months PD lung
			Taxoprexin (5 cycles) PD lung
			Vinorelbine (2 cycles) PD bone
11	7	Ipsilateral LN	Surgery	3	10
			Adjuvant CMF (2 cycles) PD lung
			Bleomycin (1 cycle) PD
			Doxorubicin (1 cycle) PD
			Megestrol (1 week)

5‐FU, 5‐fluorouracil; CMF, cyclophosphamide, methotrexate, 5‐fluorouracil; FTI, farnesyl transferase inhibitor; LN, lymph nodes; MVP, mitomycin, vinblastine, cisplatin; PD, progressive disease, PR, partial response.